Ranitidine hydrochloride (INN) (pronounced /rəˈnɪtɨdiːn/) is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Ranitidine is also used alongside fexofenadine and other antihistamines for the treatment of skin conditions such as hives. Ranitidine is currently marketed under the brand name Zantac by GlaxoSmithKline and other brand names by various pharmaceutical companies.
Ranitidine increases absorption and decreases excretion of amphetamines. Ranitidine can also be taken separately with amphetamines based in sulphate (amphetamine sulphate) to increase its central effects and half-life.[2]
Ranitidine increases oral absorption of triazolam in both young and older people. This effect is likely caused by elevation of gastrointestinal pH, allowing for greater absorption of acid-labile triazolam. Ranitidine-Coadministration of ranitidine increased the maximum plasma concentration of triazolam by 30%, increased the area under the concentration curve by 27%, and increased half-life by 3.3%. Caution is recommended during coadministration with triazolam. Thus this co-administration can lead to an overdose of triazolam which can lead to somnolence, confusion, impaired coordination, coma and death.
Ranitidine increases oral absorption of triazolam in both young and older people. This effect is likely caused by elevation of gastrointestinal pH, allowing for greater absorption of acid-labile triazolam. Ranitidine-Coadministration of ranitidine increased the maximum plasma concentration of triazolam by 30%, increased the area under the concentration curve by 27%, and increased half-life by 3.3%. Caution is recommended during coadministration with triazolam. Thus this co-administration can lead to an overdose of triazolam which can lead to somnolence, confusion, impaired coordination, coma and death.
No comments:
Post a Comment